Optimizing intrapleural bevacizumab dosing in non-small-cell lung cancer-mediated malignant pleural effusion: less is more.

doi:10.2217/fon-2018-0089

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Optimizing intrapleural bevacizumab dosing in non-small-cell lung cancer-mediated malignant pleural effusion: less is more.

Future oncology (London, England) - 1 Sept 2018

Chen Dawei, Song Xinyu, Zhang Yan, Kong Li, Wang Haiyong, Yu Jinming

Abstract excerpt

AIM: Intrapleural infusion of bevacizumab (BEV) is an emerging clinical treatment for malignant pleural effusion, but many details of usage need to be determined, especially for the effective dose. PATIENTS & METHODS: We performed a retrospective study of the records of malignant pleural effusion patients from non-small-cell lung cancer who underwent intrapleural infusion of BEV. According to the BEV dose...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to Bevacizumab
Share to Biomarkers, Tumor
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Kaplan-Meier Estimate

Share to Neoplasm Grading

Share to Neoplasm Staging

Share to Pleural Effusion, Malignant

Source

Open in PubMed

Identifiers

PMID: 29546764
DOI: 10.2217/fon-2018-0089

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.